The NTX assay in the follow-up of the osteoporotic patients: 3 years of alendronate treatment.

[1]  M. Passeri,et al.  Acute effects of bisphosphonates on new and traditional markers of bone resorption , 1995, Calcified Tissue International.

[2]  C. Christiansen,et al.  Different effects of bisphosphonate and estrogen therapy on free and peptide‐bound bone cross‐links excretion , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  H. Genant,et al.  Monitoring bone resorption in early postmenopausal women by an immunoassay for cross‐linked collagen peptides in urine , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  F. Singer,et al.  Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. , 1992, Clinical chemistry.

[5]  P. Croucher,et al.  Histomorphometric assessment of trabecular bone remodelling in osteoporosis. , 1991, Bone and mineral.

[6]  L. Deftos.  Bone protein and peptide assays in the diagnosis and management of skeletal disease. , 1991, Clinical chemistry.

[7]  C. Christiansen,et al.  Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  C. Christiansen,et al.  The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones. , 1991, Metabolism: clinical and experimental.

[9]  D. Uebelhart,et al.  Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. , 1990, Bone and mineral.

[10]  M. Caleffi,et al.  Osteocalcin: a potential marker of metastatic bone disease and response to treatment. , 1988, European journal of cancer & clinical oncology.

[11]  S. Krane,et al.  Procollagen type I carboxy‐terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  C. Christiansen,et al.  PREDICTION OF RAPID BONE LOSS IN POSTMENOPAUSAL WOMEN , 1987, The Lancet.

[13]  J. Stepan,et al.  Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism. , 1987, The Journal of clinical endocrinology and metabolism.

[14]  K. Lau,et al.  Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. , 1987, Clinical chemistry.

[15]  H. Kiefer,et al.  Plasmakreatinin als grober Indikator der Nierenfunktion* , 1964 .